StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$28.05−0.41 (-1.44%)

Close on Nov 19, 2026Market cap $4.48BP/E –Yield –

Adaptive Biotechnologies free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Adaptive Biotechnologies's free cash flow for the twelve months ending Jun 30, 2026 was -$24.03M. For fiscal 2025 it was -$48.95M. The highest annual figure on record is $194.20M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.95M–
FY2024Dec 31, 2024-$98.88M–
FY2023Dec 31, 2023-$167.02M–
FY2022Dec 31, 2022-$200.29M–
FY2021Dec 31, 2021-$254.47M–
FY2020Dec 31, 2020-$168.49M-186.8%
FY2019Dec 31, 2019$194.20M–
FY2018Dec 31, 2018-$38.56M–
FY2017Dec 31, 2017-$37.28M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.58M–
Q1 FY2026Mar 31, 2026-$10.33M–
Q4 FY2025Dec 31, 2025$1.42M–
Q3 FY2025Sep 30, 2025-$7.54M–
Q2 FY2025Jun 30, 2025-$13.09M–
Q1 FY2025Mar 31, 2025-$29.74M–
Q4 FY2024Dec 31, 2024-$12.57M–
Q3 FY2024Sep 30, 2024-$27.41M–
Q2 FY2024Jun 30, 2024-$19.03M–
Q1 FY2024Mar 31, 2024-$39.86M–
Q4 FY2023Dec 31, 2023-$28.23M–
Q3 FY2023Sep 30, 2023-$49.46M–
Q2 FY2023Jun 30, 2023-$27.25M–
Q1 FY2023Mar 31, 2023-$62.08M–
Q4 FY2022Dec 31, 2022-$32.56M–
Q3 FY2022Sep 30, 2022-$47.84M–
Q2 FY2022Jun 30, 2022-$52.36M–
Q1 FY2022Mar 31, 2022-$67.53M–
Q4 FY2021Dec 31, 2021-$63.07M–
Q3 FY2021Sep 30, 2021-$58.06M–
Q2 FY2021Jun 30, 2021-$59.25M–
Q1 FY2021Mar 31, 2021-$74.09M–
Q4 FY2020Dec 31, 2020-$49.21M–
Q3 FY2020Sep 30, 2020-$51.36M–
Q2 FY2020Jun 30, 2020-$33.34M–
Q1 FY2020Mar 31, 2020-$34.57M-112.6%
Q4 FY2019Dec 31, 2019-$29.21M–
Q3 FY2019Sep 30, 2019-$33.57M–
Q2 FY2019Jun 30, 2019-$17.49M–
Q1 FY2019Mar 31, 2019$274.47M–
Q4 FY2018Dec 31, 2018-$7.91M–
Q3 FY2018Sep 30, 2018-$13.88M–

More Adaptive Biotechnologies figures

See a number that looks wrong?